Phase II Dutasteride in Combination With CAB vs CAB in SDC
Status:
Not yet recruiting
Trial end date:
2027-09-01
Target enrollment:
Participant gender:
Summary
Phase 2 clinical trial on the addition of dutasteride to combined androgen blockade (CAB)
therapy in recurrent and/or metastatic (R/M) salivary duct carcinoma (SDC) patients.
The study will include two cohorts of patients: Cohort A, which comprises ADT-naïve patients,
and Cohort B, which comprises ADT-resistant patients.